| Name | Title | Contact Details |
|---|
Aduro Biotech, Inc. is an immunotherapy company focused on the discovery, development and commercialization of therapies that transform the treatment of challenging diseases. Aduro`s technology platforms, which are designed to harness the body`s natural immune system, are being investigated in cancer indications and have the potential to expand into autoimmune and infectious diseases. Aduro`s LADD technology platform is based on proprietary attenuated strains of Listeria that have been engineered to express tumor-associated antigens to induce specific and targeted immune responses. Based on compelling clinical data in advanced cancers, this platform is being developed as a treatment for multiple indications, including pancreatic, ovarian, lung and prostate cancers, mesothelioma and glioblastoma. Aduro`s STING Pathway Activator platform is designed to activate the intracellular STING receptor, resulting in a potent tumor-specific immune response. Aduro`s B-select monoclonal antibody platform includes a number of immune modulating assets in research and preclinical development. Aduro is collaborating with leading global pharmaceutical companies to expand its products and technology platforms.
The science of co-creation drives our quest to engineer life-changing immunology solutions, the resilient spirit of patients fuels our urgency to deliver them.
BioXcel is a Branford, CT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Alchemy GS is a Mc Lean, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
AMIGENICS is a Las Vegas, NV-based company in the Healthcare, Pharmaceuticals, and Biotech sector.